Remove 2014 Remove Clinical Trials Remove Patients
article thumbnail

Wake Network Retains CRO Santé Cannabis to Conduct Clinical Trials in Psilocybin Therapies

Cannabis Law Report

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol.

article thumbnail

8 famous people you didn’t know were cannabis patients

The Cannigma

There are cannabis users, patients, and just everyday fans who may be fans, but don’t make it a big part of their public persona. For these famous medical cannabis patients and supporters, it is something that can improve quality of life and which should be made readily available to anyone in need. 1) Patrick Stewart. It’s tricky.”.

Patients 119
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

European Regulatory Lead MAPS PBC Santa Cruz, CA

Cannabis Law Report

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. Founded in 2014, MAPS PBC is a Public Benefit Corporation that prioritizes public benefit over profit. European Regulatory Lead Executive Summary. Key Responsibilities.

article thumbnail

Santé Cannabis and Spectrum Therapeutics Launch Transformative Medical Cannabis Training Program for Québec Healthcare Professionals

Puff Puff Post

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. “It is our duty as physicians to understand the available treatment options for our patients, and medical cannabis treatments have emerged as an important clinical tool.

Programs 108
article thumbnail

Missouri Republican,Michael Davis, proposes adding access to LSD, MDMA, peyote, and psilocybin as treatment options

Cannabis Law Report

Right-to-try aims to allow patients who have been diagnosed with life-threatening diseases or conditions who have tried all approved treatment options and who are unable to participate in a clinical trial to access certain unapproved treatments. Right-to-try permits those patients to have access to investigational drugs.

article thumbnail

New Frontiers in the Law of Psychedelics

Cannabis Law Report

Patients would participate in therapy sessions to prepare for the use of psychedelics, after which the substances would be administered under the guidance and supervision of trained medical professionals. See Usona Institute, A Study of Psilocybin for Major Depressive Disorder (MDD) , Clinical Trial ID NCT03866174, available at [link].

Law 81
article thumbnail

U.S. Funding Focuses on Marijuana’s Harms, Not Benefits

CannaMD

His findings are sure to alarm medical cannabis professionals and patients alike. Furthermore, since 2014, the U.S. While the government may be behind, CannaMD physicians are leading the charge – collaborating on multiple university research studies and educating patients at every opportunity. Funding of Marijuana Research.

DEA 105